Asian Spectator

ACN Newswire Business

Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20

  • Written by ACN Newswire - Press Releases

Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20

TOKYO, Mar 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on lenvatinib mesylate (brand name: LENVIMA, lenvatinib), the orally available multikinase inhibitor discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development '20 by the PSJ.The PSJ Award for Drug Research and Development is one of a series of awards presented by the PSJ and is dedicated to researchers who have conducted outstanding research work that has contributed to medicine through the innovative development of a pharmaceutical drug or applicable technology related to the pharmaceutical sciences. Award recipients are evaluated by the PSJ based on the ingenuity of the research itself as well as the effectiveness and safety of the related pharmaceutical product(s) or the innovativeness of the related medical treatment or treatment technology. The PSJ Award for Drug Research and Development was introduced by the PSJ in 1988, with Eisai previously receiving the award for drug discovery research in 1998 on donepezil hydrochloride, an Alzheimer's disease treatment, and in 2013 on eribulin mesylate, an anti-cancer agent.The reasons for the selection of this discovery research for the award are outlined by the PSJ as follows. First, Eisai researchers created lenvatinib as a new type of kinase inhibitor with type V binding mode through a creation of the original screening models reflecting human disease and refined optimization of leading compounds. Furthermore, lenvatinib mesylate demonstrated antitumor activity against various types of cancer in clinical trials, which was accomplished with strategic application of drug properties to selectively inhibit kinases associated with tumor growth and pathogenic angiogenesis. At the time of application for the award, lenvatinib mesylate received approval as a treatment for refractory thyroid cancer, unresectable hepatocellular carcinoma, and advanced renal cell carcinoma. Finally, lenvatinib discovery research realized an innovative drug that received the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) and holds high potential to contribute to anticancer therapy worldwide.Currently, lenvatinib has been approved as a treatment for refractory thyroid cancer in more than 60 countries including Japan, the United States, and in Europe; as a treatment for unresectable hepatocellular carcinoma in more than 55 countries including Japan, the United States, in Europe, China and in Asia; as well as in combination with everolimus as a treatment for advanced renal cell carcinoma (second-line) in more than 50 countries including the United States, in Europe and in Asia. Additionally, it is also approved in the combination treatment of lenvatinib plus KEYTRUDA (pembrolizumab) for advanced endometrial carcinoma in the United States, Australia, and Canada.Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai is committed to exploring the potential clinical benefits of lenvatinib and aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Crypto.com Exchange Features ETH on The Syndicate Lite

HONG KONG, April 1, 2020 /PRNewswire-AsiaNet/ -- Crypto.com is pleased to announce the listing of Ethereum (ETH) on The Syndicate Lite platform. All Crypto.com token (CRO) token stakers will...

Yincheng Life Service Announced 2019 Annual Results

HONG KONG, Apr 1, 2020 - (ACN Newswire) - On 31 March 2020, A leading enterprise in the property management industry in Nanjing and Jiangsu Province, the PRC, Yincheng Life Service Co., Ltd...

NetFoundry Simplifies IoT Edge Compute and Private 5G

CHARLOTTE, North Carolina, April 1, 2020 /PRNewswire-AsiaNet/ -- - Embedded NetFoundry networking integrates with Microsoft Azure Edge ZonesNetFoundry [https://netfoundry.io/], a leader in z...

Points Technology Raised Multi-million Dollar Series A from K2VC

BEIJING, April 1, 2020 /PRNewswire-AsiaNet/ -- Recently, Points Technology, a blockchain and AI startup announced multi-million US dollar worth Series A financing. The investment was made by...

The Sleuth of Ming Dynasty produced by Jackie Chan to air on A...

BEIJING, April 1, 2020 /PRNewswire-AsiaNet/ -- - A sixth rank official and an embroidered uniform guard join hands to solve a series of murder casesThe light comedy The Sleuth of Ming Dynast...

EW Nutrition Launches Industry-leading Webinar Series With Top...

VISBEK, Germany, April 1, 2020 /PRNewswire-AsiaNet/ -- Yesterday, German-based company EW Nutrition took a first step toward serving the animal production industry in these challenging times...

GAC MOTOR Responds to COVID-19 Epidemic with Prevention, Prote...

GUANGZHOU, China, April 1, 2020 /PRNewswire-AsiaNet/ -- In response to the COVID-19 outbreak, GAC MOTOR has introduced various preventative measures to protect its customers and employees, w...

Huawei Maintains Steady Growth in the Enterprise Market in 2019

SHENZHEN, China, April 1, 2020 /PRNewswire-AsiaNet/ -- Powering Industry Digitization with Robust Developments in 5G, AI and CloudHuawei released its 2019 Annual Report yesterday, detailing ...

Landis+Gyr Selected by HK Electric for AMI Roll Out

SYDNEY, April 1, 2020 /PRNewswire-AsiaNet/ -- --The contract includes an opportunity to optimise the utility's grid operations by leveraging Landis+Gyr Advanced Grid Analytics technologyLand...

Suprema marks 20th Anniversary with a New Emblem

SEOUL, KOREA, Apr 1, 2020 - (ACN Newswire) - Suprema, a leading global provider of security and biometrics, is celebrating its 20th anniversary this year with an anniversary emblem, to comm...

Chun Wo's Second Innovation Student Awards Open For Application

HONG KONG, Apr 1, 2020 - (ACN Newswire) - Chun Wo Development Holdings Limited ("Chun Wo"), a key member of Asia Allied Infrastructure Holdings Limited ("Asia Allied Infrastructure" or "the...

Introducing Cytiva -- Global Life Sciences Leader

AMERSHAM, United Kingdom, Apr. 1, 2020 /PRNewswire-AsiaNet/-- - New Danaher operating company created following completion of $21.4B acquisition by Danaher Corporation- Previously GE Healthc...

DENSO Invests in Certhon Group, a greenhouse provider based in the Netherlands

KARIYA, JAPAN, Apr 1, 2020 - (JCN Newswire) - DENSO Corporation, the second largest advanced automotive technology supplier in the world, has announced its investment in Certhon Group (Cert...

Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China

TOKYO, Apr 1, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China ...

"Smart Construction Sites" Established to Guarantee that the V...

CHENGDU, China, Mar. 31, 2020 /Xinhua-AsiaNet/-- World University Games 2021 will be held in Chengdu, China. To get to know more about Chengdu and the event, please visit: www.gochengdu.cn.A...

Yincheng International Announces 2019 Annual Results, Revenue Significantly Grew by 77.8% to RMB 9.01 billion

HONG KONG, Apr 1, 2020 - (ACN Newswire) - An established property developer in the PRC focuses on developing quality residential properties in the Yangtze River Delta Megalopolis for custom...

Fashion Destination K11 MUSEA MUSE EDITION Launches First-Ever Global Fashion Venture K11|ANTONIA

Spread across 5,700 sq ft, the K11|ANTONIA flagship debuts at K11 MUSEA MUSE EDITION, the cutting-edge fashion destination for fashion insiders, with over 50 looks curated by founder Ant...

SKYWORTH leads the new AIoT decade with 2020 SKYWORTH Global T...

SHENZHEN, China, April 1, 2020 /PRNewswire-AsiaNet/ -- SKYWORTH, a leading global television brand and the pioneer of big-screen AIoT, announced the return of the 2020 SKYWORTH Global Televi...

Introducing SENTR™ by Primal: Asia’s First Campaign Management Platform (CMP)

Leading Local Agency Launches the Regions First Hybrid Customer Relationship Management and Project Management Tool KUALA LUMPUR, MALAYSIA - Media OutReach - 1 April 2020 - L...



News Company Media Core

Content & Technology Connecting Global Audiences

More Information - Less Opinion